A Phase 2, Randomized, Double-blind,Placebo-controlled Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy.

Trial Profile

A Phase 2, Randomized, Double-blind,Placebo-controlled Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Belnacasan (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2011 Status changed from active, no longer recruiting to completed.
    • 21 Oct 2010 Planned end date changed from 1 Sep 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 21 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top